Gerry Hanna, Marie Curie Chair of Clinical Oncology at Trinity College Dublin, shared a post on X:
“1st up in this morning’s WCLC25 plenary is the ECOG-ARIN EA5181 study
662 patients randomised to Concurrent ChemoRT vs concurrent ChemoRT + Durvalumab
Obsolutely no difference in OS or PFS in either arm.
Thankfully no major uptick in toxicity.
Making sense of it all is discussant Corinne Faivre-Finn at WCLC25
The immune system needs the right ‘window’
Might induction ChemoIO be a better route?”
More posts featuring Gerry Hanna.